| Literature DB >> 34582428 |
Lama A Al-Aswad1, Cansu Yuksel Elgin1, Vipul Patel1, Deborah Popplewell2, Kalashree Gopal2, Dan Gong2, Zach Thomas2, Devon Joiner2, Cha-Kai Chu2, Stephen Walters2, Maya Ramachandran2, Rahul Kapoor2, Maribel Rodriguez, Jennifer Alcantara-Castillo1, Gladys E Maestre3, Joseph H Lee2, Golnaz Moazami2.
Abstract
PURPOSE: To examine the benefits and feasibility of a mobile, real-time, community-based, teleophthalmology program for detecting eye diseases in the New York metro area.Entities:
Mesh:
Year: 2021 PMID: 34582428 PMCID: PMC8794049 DOI: 10.1097/APO.0000000000000416
Source DB: PubMed Journal: Asia Pac J Ophthalmol (Phila) ISSN: 2162-0989
FIGURE 1.A, Teleophthalmology mobile unit. B, Inside of the mobile van.
Demographics and Patient Characteristics
| Characteristics | Total (n = 957) | Healthy Ocular Findings (n = 499) | Ophthalmology Referred Patients (n = 458) | Glaucoma Suspects (n = 305) | Anatomic Narrow Angle Suspects (n = 136) | Cataract Suspects (n = 124) | AMD Suspects (n = 9) | Retinal Disorders Suspects (n = 29) | Other Ocular Findings (n = 97) |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Age, mean ± std | 57.72 ± 12.92 | 54.49 ± 13.01 | 61.24 ± 11.87 | 61.6 ± 11.25 | 59.74 ± 9.61 | 67.77 ± 10.9 | 67.89 ± 11.49 | 62.31 ± 9.55 | 60.20 ± 12.11 |
| 18≤ age ≤44, n (%) | 142 (15%) | 104 (21%) | 38 (8%) | 17 (6%) | 6 (4%) | 3 (2%) | 0 (0%) | 1 (3%) | 12 (12%) |
| 45≤ age ≤54, n (%) | 217 (23%) | 133 (27%) | 84 (18%) | 60 (20%) | 34 (25%) | 12 (10%) | 1 (11%) | 7 (24%) | 16 (16%) |
| 55≤ age ≤64 | 318 (33%) | 136 (27%) | 148 (32%) | 104 (34%) | 53 (39%) | 36 (29%) | 3 (33%) | 9 (31%) | 30 (31%) |
| Age ≥65 | 280 (29%) | 126 (25%) | 188 (41%) | 124 (41%) | 43 (32%) | 73 (59%) | 5 (56%) | 12 (41%) | 39 (40%) |
| Gender, n (%) | |||||||||
| Female | 519 (54%) | 278 (56%) | 241 (%) | 162 (53%) | 85 (63%) | 64 (52%) | 7 (78%) | 11 (38%) | 51 (53%) |
| Male | 438 (46%) | 221 (44%) | 217 (%) | 143 (47%) | 51 (38%) | 60 (48%) | 2 (22%) | 18 (62%) | 46 (47%) |
| Ethnicity, n (%) | |||||||||
| African American | 300 (31%) | 142 (28%) | 158 (34%) | 107 (35%) | 43 (32%) | 34 (27%) | 4 (44%) | 7 (24%) | 27 (28%) |
| Asian | 94 (10%) | 52 (10%) | 42 (9%) | 26 (9%) | 11 (8%) | 12 (10%) | 4 (44%) | 1 (3%) | 10 (10%) |
| Caucasian | 55 (6%) | 35 (7%) | 20 (4%) | 14 (5%) | 3 (2%) | 14 (11%) | 0 (0%) | 1 (3%) | 3 (3%) |
| Hispanic | 443 (46%) | 235 (47%) | 208 (45%) | 140 (46%) | 68 (50%) | 59 (48%) | 1 (11%) | 18 (62%) | 46 (47%) |
| Other | 65 (7%) | 35 (7%) | 28 (6%) | 17 (6%) | 11 (8%) | 5 (4%) | 0 (0%) | 2 (7%) | 9 (9%) |
| Self-declaration, n (%) | |||||||||
| Insurance | 738 (77%) | 383 (77%) | 355 (78%) | 231 (76%) | 100 (74%) | 21 (72%) | 9 (100%) | 21 (72%) | 86 (89%) |
| Current smoker | 182 (19%) | 89 (18%) | 93 (20%) | 57 (19%) | 27 (20%) | 23 (19%) | 2 (22%) | 7 (24%) | 17 (18%) |
| Sleep apnea | 93 (10%) | 49 (10%) | 44 (10%) | 26 (9%) | 9 (7%) | 14 (11%) | 1 (11%) | 2 (7%) | 10 (10%) |
| Hypertension | 383 (40%) | 21 (4%) | 219 (48%) | 145 (48%) | 52 (38%) | 70 (56%) | 1 (11%) | 18 (62%) | 44 (45%) |
| Diabetes mellitus | 213 (22%) | 13 (3%) | 119 (26%) | 71 (23%) | 29 (21%) | 33 (27%) | 1 (11%) | 28 (97%) | 31 (32%) |
| Dyslipidemia | 302 (32%) | 20 (4%) | 163 (36%) | 113 (37%) | 46 (34%) | 45 (36%) | 1 (11%) | 14 (48%) | 32 (33%) |
| Glaucoma (all) | 62 (6%) | 12 (2%) | 50 (11%) | 44 (14%) | 10 (7%) | 14 (11%) | 0 (0%) | 6 (21%) | 5 (5%) |
| Cataracts | 113 (12%) | 41 (8%) | 72 (16%) | 48 (16%) | 12 (9%) | 30 (24%) | 3 (33%) | 14 (48%) | 12 (12%) |
| Macular degeneration | 6 (<1%) | 3 (<1%) | 3 (<1%) | 3 (1%) | 2 (1%) | 1 (1%) | 0 (0%) | 0 (0%) | 1 (1%) |
| Retinal disorders | 18 (2%) | 6 (1%) | 12 (3%) | 9 (3%) | 3 (2%) | 2 (2%) | 0 (0%) | 4 (14%) | 5 (5%) |
| Last dental exam | |||||||||
| <1 year | 622 (65%) | 319 (64%) | 303 (66%) | 196 (64%) | 87 (64%) | 75 (60%) | 8 (89%) | 16 (55%) | 66 (68%) |
| >2 years | 213 (22%) | 117 (23%) | 96 (21%) | 70 (23%) | 32 (24%) | 31 (25%) | 1 (11%) | 9 (31%) | 14 (14%) |
| >5 years | 108 (11%) | 54 (11%) | 54 (11%) | 36 (12%) | 16 (12%) | 15 (12%) | 0 (0%) | 3 (10%) | 17 (18%) |
| Never | 14 (1%) | 9 (2%) | 5 (1%) | 3 (1%) | 1 (<1%) | 3 (2%) | 0 (0%) | 1 (3%) | 0 (0%) |
| Last eye exam | |||||||||
| <1 year | 407 (43%) | 178 (36%) | 200 (44%) | 154 (50%) | 65 (48%) | 19 (66%) | 4 (44%) | 19 (66%) | 54 (56%) |
| >2 years | 317 (33%) | 180 (36%) | 108 (24%) | 98 (32%) | 43 (32%) | 4 (14%) | 2 (22%) | 4 (14%) | 21 (22%) |
| >5 years | 171 (18%) | 97 (19%) | 41 (9%) | 41 (13%) | 22 (16%) | 5 (17%) | 3 (33%) | 5 (17%) | 20 (21%) |
| Never | 61 (6%) | 43 (9%) | 6 (1%) | 12 (4%) | 6 (4%) | 1 (3%) | 0 (0%) | 1 (3%) | 2 (2%) |
Comparison of Self-Reported Diseases and Newly Detected Diseases
| Condition | Disease Detected by Screening (n = 567) | Self-Reported Within Condition | Newly Identified Disease | Self-Reported Disease, Not Identified by Screening |
|---|---|---|---|---|
|
| ||||
| Ocular conditions (all) | n = 567 | n = 129 | n = 438 | n = 107 |
| Glaucoma (all) | 305 | 44 | 261 | 18 |
| Cataract | 124 | 30 | 94 | 83 |
| Macular degeneration | 9 | 0 | 9 | 6 |
| Retinal disorders (DRP and the others) | 29 | 4 | 25 | 14 |
| Diabetes or prediabetes[ | 433 | 213 | 220 | 24 |
| Hypertension | 344 | 123 | 221 | 200 |
DRP indicates diabetic retinopathy.
Patients who self-reported a history of cataracts. No differentiation between being preop or postop.
Prediabetic state was defined as HbA1c 5.7%–6.4% and diabetes was defined as HbA1c ≥ 6.5%.
Results of Vision Testing from the Telemedicine Protocol
| Systematic Variables | Total (n = 957) | Healthy Ocular Findings (n = 499) | Ophthalmology Referred Patients (n = 458) | Glaucoma Suspects (n = 305) | Anatomic Narrow-Angle Suspects (n = 136) | Cataract Suspects (n = 124) | AMD Suspects (n = 9) | Retinal Disorders Suspects (n = 29) | Other Ocular Findings (n = 97) |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| HbA1c, mean ± std | 5.96 ± 1.26 | 5.79 ± 1.03 | 6.14 ± 1.44 | 6.15 ± 1.48 | 5.94 ± 1.18 | 6.12 ± 1.25 | 5.74 ± 0.36 | 8.72 ± 2.14 | 6.03 ± 1.45 |
| Healthy A1C (Under 5.3), n (%) | 243 (25%) | 135 (27%) | 108 (24%) | 66 (22%) | 27 (20%) | 25 (20%) | 1 (11%) | 0 (0%) | 27 (28%) |
| Treading towards prediabetes (5.4–5.6), n (%) | 279 (29%) | 167 (33%) | 112 (24%) | 86 (28%) | 41 (30%) | 23 (19%) | 4 (44%) | 2 (7%) | 22 (23%) |
| Prediabetic state (5.7–6.4), n (%) | 289 (30%) | 142 (28%) | 147 (32%) | 92 (30%) | 47 (35%) | 50 (40%) | 4 (44%) | 4 (14%) | 31 (32%) |
| Diabetic (≥6.5), n (%) | 144 (15%) | 54 (11%) | 90 (20%) | 60 (20%) | 21 (15%) | 26 (21%) | 0 (0%) | 23 (79%) | 17 (18%) |
| Systolic BP, mean ± std | 128.8 ± 19.66 | 127.02 ± 18.47 | 130.74 ± 20.72 | 130.50 ± 20.13 | 128.93 ± 20.32 | 134.97 ± 21.48 | 125.56 ± 23.67 | 137.69 ± 24.75 | 126.48 ± 19.79 |
| Diastolic BP, mean ± std | 78.81 ± 12.02 | 78.39 ± 12.33 | 79.27 ± 11.67 | 79.47 ± 11.77 | 78.10 ± 11.01 | 78.77 ± 11.35 | 73.67 ± 12.13 | 79.76 ± 10.58 | 76.18 ± 10.32 |
| Low BP, n (%) | 10 (1%) | 5 (1%) | 5 (1%) | 3 (1%) | 2 (1%) | 3 (2%) | 0 (0%) | 0 (0%) | 2 (2%) |
| Normal BP, (%) | 314 (33%) | 184 (37%) | 131 (29%) | 85 (28%) | 41 (30%) | 26 (21%) | 5 (56%) | 8 (28%) | 35 (36%) |
| Pre-HT, n (%) | 266 (28%) | 130 (26%) | 136 (30%) | 88 (29%) | 45 (33%) | 44 (35%) | 0 (0%) | 5 (17%) | 32 (33%) |
| Stage 1 HT, n (%) | 115 (12%) | 62 (12%) | 53 (12%) | 40 (13%) | 15 (11%) | 12 (10%) | 2 (22%) | 3 (10%) | 13 (13%) |
| Stage 2 HT, n (%) | 243 (25%) | 115 (23%) | 128 (28%) | 87 (29%) | 33 (24%) | 36 (29%) | 2 (22%) | 11 (38%) | 14 (14%) |
| Hypertensive urgency, n (%) | 8 (<1%) | 3 (<1%) | 5 (1%) | 2 (1%) | 0 (0%) | 3 (2%) | 0 (0%) | 2 (7%) | 1 (1%) |
| BMI, mean ± std | 28.36 ± 5.86 | 28.64 ± 6.03 | 28.05 ± 5.66 | 27.89 ± 5.46 | 28.16 ± 6.29 | 28.38 ± 6.68 | 28.36 ± 8.76 | 30.58 ± 6.76 | 27.71 ± 5.71 |
| Normal range (18.5–24.9), n (%) | 265 (28%) | 127 (25%) | 138 (30%) | 94 (31%) | 39 (29%) | 40 (32%) | 5 (56%) | 4 (14%) | 30 (31%) |
| Elevated (25–29.9), n (%) | 393 (42%) | 206 (41%) | 187 (41%) | 123 (40%) | 55 (40%) | 45 (36%) | 1 (11%) | 11 (38%) | 42 (43%) |
| High (≥30), n (%) | 299 (31%) | 166 (33%) | 133 (29%) | 88 (29%) | 42 (31%) | 39 (31%) | 3 (33%) | 14 (48%) | 25 (26%) |
AMD indicates age-related macular degeneration; BMI, body mass index; BP, blood pressure; HbA1c, hemoglobin A1c; HT, hypertension.
Results of Vision Testing from the Telemedicine Protocol
| Ocular Variables | Total (n = 957) | Healthy Ocular Findings (n = 499) | Ophthalmology Referred Patients (n = 458) | Glaucoma Suspects (n = 305) | Anatomic Narrow-Angle Suspects | Cataract Suspects (n = 124) | AMD Suspects (n = 9) | Retinal Disorders Suspects (n = 29) | Other Ocular Findings (n = 97) |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| VA (logMAR), mean ± std | |||||||||
| Right eye | 0.31 ± 0.32 | 0.26 ± 0.28 | 0.37 ± 0.35 | 0.34 ± 0.32 | 0.29 ± 0.20 | 0.52 ± 0.47 | 0.34 ± 0.19 | 0.67 ± 0.52 | 0.35 ± 0.36 |
| Left eye | 0.35 ± 0.42 | 0.27 ± 0.29 | 0.43 ± 0.51 | 0.41 ± 0.50 | 0.33 ± 0.40 | 0.55 ± 0.53 | 0.36 ± 0.28 | 0.74 ± 0.73 | 0.34 ± 0.31 |
| IOP (mm Hg), mean ± std | |||||||||
| Right eye | 15.13 ± 4.23 | 14.46 ± 3.11 | 15.86 ± 5.09 | 16.79 ± 5.50 | 15.65 ± 4.46 | 15.34 ± 4.34 | 16.33 ± 3.77 | 15.10 ± 4.62 | 13.80 ± 3.45 |
| Left eye | 15.27 ± 4.46 | 14.56 ± 3.16 | 16.04 ± 5.45 | 16.89 ± 6.00 | 15.77 ± 4.33 | 15.57 ± 4.74 | 15.89 ± 4.86 | 15.46 ± 5.31 | 14.07 ± 3.49 |
| CCT (μm), mean ± std | |||||||||
| Right eye | 544.56 ± 40.43 | 543.31 ± 39.14 | 545.86 ± 41.73 | 545.89 ± 40.61 | 546.45 ± 39.84 | 544.26 ± 42.61 | 550.00 ± 36.90 | 559.31 ± 32.04 | 548.77 ± 38.17 |
| Left eye | 545.19 ± 40.41 | 544.54 ± 38.96 | 545.90 ± 41.97 | 547.07 ± 41.12 | 547.95 ± 39.50 | 546.46 ± 46.45 | 552.00 ± 43.50 | 545.70 ± 27.19 | 550.68 ± 34.97 |
| Reader: VCDR, mean ± std | |||||||||
| Right eye | 0.37 ± 0.18 | 0.33 ± 0.14 | 0.42 ± 0.20 | 0.46 ± 0.21 | 0.38 ± 0.18 | 0.38 ± 0.19 | 0.40 ± 0.13 | 0.42 ± 0.20 | 0.35 ± 0.16 |
| Left eye | 0.38 ± 0.18 | 0.34 ± 0.14 | 0.42 ± 0.21 | 0.47 ± 0.22 | 0.38 ± 0.18 | 0.37 ± 0.22 | 0.39 ± 0.10 | 0.46 ± 0.21 | 0.36 ± 0.17 |
| OCT: VCDR, mean ± std | |||||||||
| Right eye | 0.56 ± 0.20 | 0.53 ± 0.18 | 0.58 ± 0.21 | 0.62 ± 0.21 | 0.57 ± 0.19 | 0.56 ± 0.23 | 0.58 ± 0.19 | 0.50 ± 0.25 | 0.52 ± 0.22 |
| Left eye | 0.56 ± 0.21 | 0.54 ± 0.19 | 0.58 ± 0.22 | 0.63 ± 0.20 | 0.58 ± 0.18 | 0.52 ± 0.26 | 0.58 ± 0.11 | 0.54 ± 0.24 | 0.53 ± 0.23 |
| RNFL (μm), mean ± std | |||||||||
| Right eye | 105.17 ± 16.70 | 109.99 ± 11.61 | 99.88 ± 19.60 | 98.82 ± 20.28 | 105.40 ± 16.79 | 97.78 ± 20.52 | 109.56 ± 9.77 | 97.59 ± 23.18 | 100.63 ± 20.21 |
| Left eye | 104.19 ± 16.94 | 108.58 ± 11.72 | 99.30 ± 20.23 | 97.71 ± 20.51 | 105.57 ± 16.64 | 98.56 ± 17.26 | 112.89 ± 7.37 | 92.17 ± 25.00 | 100.03 ± 20.21 |
| FDT-VF (μm), mean ± std | |||||||||
| Right eye, avg misses | 1.56 ± 3.23 | 0.86 ± 2.23 | 2.32 ± 3.92 | 1.79 ± 3.32 | 1.15 ± 2.76 | 2.38 ± 4.02 | 2.50 ± 5.90 | 6.14 ± 6.05 | 3.79 ± 4.34 |
| Left eye, avg misses | 1.69 ± 3.68 | 0.81 ± 2.31 | 2.68 ± 4.57 | 2.12 ± 4.05 | 1.23 ± 3.08 | 2.55 ± 4.66 | 3.13 ± 6.27 | 5.96 ± 6.43 | 4.46 ± 5.37 |
AMD indicates age-related macular degeneration; CCT, central corneal thickness; FDT-VF, frequency doubling technology visual field; IOP, intraocular pressure; OCT, optical coherence tomography; RNFL, retinal nerve fiber layer; VA, visual acuity; VCDR, vertical cup-to-disc ratio.
Results of Relative Risk Ratio from the Telemedicine Protocol
| Healthy Ocular Findings RRR (95%) | Ophthalmology Referred Patients RRR (95%) | Glaucoma Referred | Narrow-Angle Referred | Cataract Referred | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||
| Age (relative to group age 18–44) | ||||||||||
| 45≤ age ≤54 | 0.84 (0.72–0.97) | 0.02 | 1.45 (1.05–1.99) | 0.02 | 2.31 (1.41–3.79) | 0.00 | 3.71 (1.60–8.60) | 0.00 | 2.62 (0.75–9.11) | 0.13 |
| 55≤ age ≤64 | 0.65 (0.56–0.76) | 0.00 | 1.97 (1.45–2.61) | 0.00 | 3.06 (1.91–4.90) | 0.00 | 4.42 (1.95–10.03) | 0.00 | 5.17 (1.61–16.61) | 0.01 |
| Age ≥65 | 0.54 (0.46–0.65) | 0.00 | 2.24 (1.68–2.98) | 0.00 | 3.30 (2.07–5.26) | 0.00 | 3.24 (1.41–7.44) | 0.01 | 11.76 (3.78–36.62) | 0.00 |
| Gender (relative to male) | ||||||||||
| Female | 1.06 (0.94–1.20) | 0.34 | 0,94 (0.82–1.07) | 0.34 | 0.96 (0.79–1.15) | 0.64 | 1.41 (1.02–1.94) | 0.04 | 0.90 (0.65–1.25) | 0.53 |
| Ethnicity (relative to Caucasian) | ||||||||||
| Hispanic | 0.83 (0.67–1.04) | 0.10 | 1.29 (0.90–1.86) | 0.17 | 1.24 (0.77–1.99) | 0.37 | 2.81 (0.92–8.64) | 0.07 | 0.52 (0.31–0.87) | 0.01 |
| African American | 0.74 (0.59–0.94) | 0.01 | 1.45 (1.01–2.09) | 0.05 | 1.40 (0.87–2.26) | 0.17 | 2.63 (0.85–8.17) | 0.10 | 0.45 (0.26–0.77) | 0.00 |
| Asian | 0.87 (0.66–1.14) | 0.31 | 1.23 (0.81–1.86) | 0.33 | 1.09 (0.62–1.90) | 0.77 | 2.15 (0.63–7.36) | 0.23 | 0.50 (0.25–1.00) | 0.05 |
| Others | 0.85 (0.63–1.14) | 0.28 | 1.27 (0.82–1.97) | 0.29 | 1.09 (0.60–1.98) | 0.78 | 3.10 (0.91–10.56) | 0.07 | 0.30 (0.12–0.79) | 0.01 |
| Self-report Conditions | ||||||||||
| Presence of insurance | 0.98 (0.85–1.13) | 0.77 | 1.02 (0.87–1.20) | 0.78 | 0.93 (0.75–1.15) | 0.51 | 0.84 (0.59–1.20) | 0.34 | 0.92 (0.63–1.35) | 0.67 |
| Smoking | 0.92 (0.79–1.09) | 0.34 | 1.08 (0.92–1.27) | 0.32 | 0.98 (0.77–1.24) | 0.86 | 1.05 (0.71–1.56) | 0.79 | 0.97 (0.64–1.48) | 0.89 |
| Sleep apnea | 1.01 (0.83–1.24) | 0.91 | 0.99 (0.79–1.24) | 0.91 | 0.87 (0.62–1.22) | 0.41 | 0.66 (0.35–1.25) | 0.20 | 1.18 (0.71–1.98) | 0.52 |
| Personal history of hypertension | 0.73 (0.64–0.84) | 0.00 | 1.37 (1.21–1.56) | 0.00 | 1.36 (1.13–1.63) | 0.00 | 0.93 (0.67–1.28) | 0.65 | 1.94 (1.40–2.70) | 0.00 |
| Personal history of DM | 0.81(0.69–0.96) | 0.01 | 1.23 (1.06–1.41) | 0.00 | 1.06 (0.85–1.32) | 0.60 | 0.95 (0.65–1.39) | 0.78 | 1.27(0.88–1.83) | 0.21 |
| Personal history of dyslipidemia | 0.84 (0.73–0.96) | 0.01 | 1.19 (1.05–1.37) | 0.01 | 1.28 (1.06–1.54) | 0.01 | 1.11 (0.80–1.54) | 0.54 | 1.24 (0.88–1.74) | 0.22 |
| Personal history of glaucoma | 0.35 (0.21–0.59) | 0.00 | 1.77 (1.53–2.04) | 0.00 | 2.43 (2.01–2–94) | 0.00 | 1.14 (0.63–2.06) | 0.65 | 1.84 (1.12–3.00) | 0.02 |
| Personal history of cataract | 0.67 (0.52–0.86) | 0.00 | 1.39 (1.19–1.63) | 0.00 | 1.39 (1.10–1.77) | 0.01 | 0.72 (0.41–1.26) | 0.25 | 2.38 (1.66–3.42) | 0.00 |
| Last dental exam (related to less than 1 year) | ||||||||||
| Last dental exam >2 years | 1.07 (0.92–1.24) | 0.35 | 0.93 (0.78–1.10) | 0.37 | 1.04 (0.83–1.31) | 0.77 | 1.07 (0.74–1.56) | 0.71 | 1.21 (0.82–1.78) | 0.34 |
| Last dental exam >5 years | 0.97 (0.80–1.20) | 0.81 | 1.03 (0.84–1.26) | 0.80 | 1.06 (0.79–1.41) | 0.71 | 1.06 (0.65–1.73) | 0.82 | 1.15 (0.69–1.93) | 0.59 |
| Last dental exam never | 1.25 (0.84–1.87) | 0.27 | 0.73 (0.36–1.49) | 0.39 | 0.68 (0.25–1.87) | 0.45 | 0.51 (0.08–3.41) | 0.49 | 1.78 (0.64–4.95) | 0.27 |
| Last eye exam (related to last eye exam less than 1 year) | ||||||||||
| Last eye exam >2 years | 1.30 (1.12–1.50) | 0.00 | 0.77 (0.66–0.89) | 0.00 | 0.82 (0.66–1.00) | 0.06 | 0.85 (0.59–1.21) | 0.37 | 0.55 (0.36–0.82) | 0.00 |
| Last eye exam >5 years | 1.30 (1.09–1.54) | 0.00 | 0.77 (0.63–0.93) | 0.01 | 0.63 (0.47–0.85) | 0.00 | 0.81 (0.51–1.26) | 0.35 | 0.74 (0.47–1.16) | 0.19 |
| Last eye exam never | 1.61 (1.32–1.96) | 0.00 | 0.52 (0.35–0.78) | 0.00 | 0.52 (0.30–0.88) | 0.01 | 0.62 (0.28–1.36) | 0.23 | 0.59 (0.27–1.30) | 0.19 |
| Presence of regular eye doctor | 0.77 (0.67–0.89) | 0.00 | 1.30 (1.14–1.49) | 0.00 | 1.22 (1.00–1.48) | 0.05 | 1.10 (0.79–1.54) | 0.58 | 1.03 (0.72–1.47) | 0.89 |
| Reported vision change | 0.92 (0.82–1.04) | 0.20 | 1.09 (0.95–1.25) | 0.20 | 0.97 (0.81–1.17) | 0.77 | 1.18 (0.85–1.62) | 0.33 | 1.73 (1.20–2.49) | 0.00 |
| Reported eye injury / surgery | 0.80 (0.68–0.95) | 0.01 | 1.24 (1.07–1.43) | 0.00 | 1.24 (1.01–1.53) | 0.04 | 1.02 (0.70–1.49) | 0.92 | 1.04 (0.70–1.54) | 0.86 |
| Systemic Findings | ||||||||||
| BMI (related to normal range 18.5–24.9) | ||||||||||
| BMI elevated (25–29.9) | 1.09 (0.93–1.28) | 0.26 | 0.91 (0.78–1.07) | 0.26 | 0.88 (0.71–1.10) | 0.26 | 0.95 (0.65–1.39) | 0.80 | 0.76 (0.51–1.13) | 0.17 |
| BMI high (≥30) | 1.16 (0.99–1.36) | 0.07 | 0.85 (0.72 –1.01) | 0.07 | 0.83 (0.65–1.05) | 0.13 | 0.95 (0.64–1.43) | 0.82 | 0.86 (0.57–1.30) | 0.48 |
| HbA1c (related to healthy A1C level <5.3) | ||||||||||
| HbA1c: Treading towards prediabetes (5.4–5.6) | 1.08 (0.93–1.25) | 0.32 | 0.90 (0.74–1.10) | 0.32 | 1.13 (0.87–1.49) | 0.36 | 1.32 (0.84–2.08) | 0.23 | 0.80 (0.47–1.37) | 0.42 |
| HbA1c: Prediabetic state (5.7–6.4) | 0.88 (0.25–1.04) | 0.14 | 1.14 (0.96–1.37) | 0.14 | 1.17 (0.90–1.53) | 0.24 | 1.46 (0.94–2.28) | 0.09 | 1.68 (1.07–2.63) | 0.02 |
| HbA1c: Diabetic (6.5 and higher) | 0.67 (0.53–0.87) | 0.00 | 1.41 (1.16–1.70) | 0.00 | 1.53 (1.16–2.03) | 0.00 | 1.31 (0.77–2.23) | 0.32 | 1.76 (1.06–2.92) | 0.03 |
| Blood pressure (related to normal blood pressure) | ||||||||||
| Prehypertension | 0.84 (0.72–0.98) | 0.02 | 1.23 (1.03–1.47) | 0.02 | 1.23 (0.96–1.57) | 0.11 | 1.29 (0.88–1.92) | 0.19 | 2.00 (1.27–3.16) | 0.00 |
| Stage 1 hypertesion | 0.92 (0.76–1.12) | 0.42 | 1.11 (0.87–1.40) | 0.40 | 1.29 (0.95–1.76) | 0.11 | 1.00 (0.58–1.74) | 0.99 | 1.26 (0.66–2.42) | 0.48 |
| Stage 2 hypertesion | 0.81 (0.69–0.95) | 0.01 | 1.27 (1.06–1.51) | 0.01 | 1.33 (1.04–1.70) | 0.03 | 1.04 (0.68–1.60) | 0.85 | 1.79 (1.12–2.89) | 0.02 |
| Hypertensive urgency | 0.64 (0.26–1.58) | 0.33 | 1.50 (0.86–2.61) | 0.15 | 0.93 (0.28–3.12) | 0.90 | 4.54 (1.73–11.95) | 0.00 | ||
| Low blood pressure (hypoTA) | 0.86 (0.46–1.60) | 0.63 | 1.20 (0.64–2.27) | 0.57 | 1.11 (0.42–2.92) | 0.83 | 1.54 (0.43–5.48) | 0.51 | 3.63 (1.32–10.04) | 0.01 |
| Ocular Findings (in either eye) | ||||||||||
| IOP >21mm Hg | 0.27 (0.17–0.41) | 0.00 | 1.99 (1.78–2.22) | 0.00 | 2.70 (2.30–3.18) | 0.00 | 1.37 (0.91–2.08) | 0.13 | 1.89 (1.28–2.78) | 0.00 |
| VCDR ≥0.5 according to specialist | 0.60 (0.51–0.70) | 0.00 | 1.60 (1.41–1.82) | 0.00 | 2.50 (2.09–3.01) | 0.00 | 1.11 (0.80–1.53) | 0.54 | 1.24 (0.89–1.73) | 0.21 |
| VCDR ≥0.7 according to specialist | 0.21 (0.11–0.39) | 0.00 | 1.99 (1.78–2.22 | 0.00 | 3.08 (2.66–3.56) | 0.00 | 0.92 (0.51–1.68) | 0.79 | 1.72 (1.07–2.75) | 0.02 |
| VCDR ≥0.5 according to OCT | 0.82 (0.72–0.94) | 0.01 | 1.27 (1.05–1.53) | 0.01 | 1.89 (1.38–2.57) | 0.00 | 1.31 (0.85–2.01) | 0.22 | 1.00 (0.66–1.51) | 0.99 |
| VCDR ≥0.7 according to OCT | 1.68 (0.58–0.79) | 0.00 | 1.45 (1.27–1.64) | 0.00 | 2.26 (1.89–2.69) | 0.00 | 0.99 (0.71–1.38) | 0.94 | 1.13 (0.80–1.60) | 0.48 |
| VF (FDT) abnormality | 0.66 (0.58–0.75) | 0.00 | 1.36 (1.28–1.46) | 0.00 | 1.22 (1.10–1.36) | 0.00 | 0.83 (0.66–1.06) | 0.13 | 1.20 (0.98–1.47) | 0.07 |
| RNFL <75 μm | 0.07 (0.02–0.21) | 0.00 | 2.04 (1.84–2.21) | 0.00 | 2.76 (2.35–3.24) | 0.00 | 1.29 (0.78–2.14) | 0.32 | 2.57 (1.74–3.79) | 0.00 |
| RNFL <95 μm | 0.44 (0.35–0.54) | 0.00 | 1.88 (1.67–2.12) | 0.00 | 2.46 (2.07–2.93) | 0.00 | 1.06 (0.75–1.50) | 0.76 | 1.85 (1.33–2.57) | 0.00 |
| CCT <535 μm | 1.06 (0.94–1.20) | 0.34 | 0.94 (0.82–1.07) | 0.35 | 0.91 (0.75–1.09) | 0.31 | 0.78 (0.57–1.07) | 0.13 | 1.07 (0.77–1.49) | 0.68 |
| CCT <510 μm | 0.98 (0.85–1.14) | 0.81 | 1.02 (0.87–1.19) | 0.81 | 1.07 (0.86–1.33) | 0.56 | 1.08 (0.75–1.56) | 0.68 | 0.98 (0.66–1.46) | 0.91 |
BMI indicates body mass index; CCT, central corneal thickness; FDT, frequency doubling technology; HbA1c, hemoglobin A1c; IOP, intraocular pressure; OCT, optical coherence tomography; RNFL, retinal nerve fiber layer; RRR, relative risk ratios; VA, visual acuity; VF, visual field; VCDR, vertical cup-to-disc ratio.
Bayesian Regression of Ophthalmological Referral (1,2,3) and Glaucoma Referral (4,5,6)
| Variables | (1) Oph. Ref. | (2) Oph. Ref. | (3) Oph. Ref. | (4) Glauc. Ref. | (5) Glauc. Ref. | (6) Glauc. Ref. |
|---|---|---|---|---|---|---|
|
| ||||||
| Age | 0.04 | 0.04 | 0.04 | 0.04 | 0.02 | 0.03 |
| Hispanic | 0.63 | 0.71 | 0.70 | 0.53 (0.40) | 0.61 (0.41) | 0.60 (0.48) |
| African American | 0.97 | 1.02 | 1.00 | 0.82 | 0.84 | 0.86 |
| Asian | 0.57 (0.38) | 0.60 (0.40) | 0.65 (0.46) | 0.38 (0.45) | 0.42 (0.47) | 0.43 (0.53) |
| Others | 0.94 | 1.00 | 1.07 | 0.62 (0.49) | 0.68 (0.50) | 0.79 (0.56) |
| HbA1c | 0.61 | 0.51 | 0.58 | 0.41 | 0.27 (0.22) | 0.48 |
| Treated glaucoma | 1.26 | 1.04 | 0.66 | 1.54 | 1.30 | 1.17 |
| IOP >21mm Hg | 2.10 | 2.04 | 2.39 | 1.98 | 1.92 | 2.27v |
| RNFL <95 μm | (0.28) | (0.29) 1.05 | (0.35) 0.80 | (0.23) | (0.24) 1.12 | (0.28) 0.89 |
| VF Abnormal | 0.66 | 0.15 | ||||
| Constant | −3.76 | −3.53 | (0.11) −3.96 | −3.92 | −3.60 | (0.10) −3.86 |
| Observations | 956 | 956 | 784 | 956 | 956 | 784 |
Robust standard errors in parentheses.
HbA1c indicates hemoglobin A1c; IOP, intraocular pressure; RNFL, retinal nerve fiber layer; VF, visual field.
P < 0.01
P < 0.05
P < 0.1
Individual Follow-up
| Disease, n | Reached, n (%) | Followed Up With Ophthalmologist, n (%) | Disease Confirmed, n (%) | Additional Eye Problem Detected, n (%) | Required Rx, n (%) |
|---|---|---|---|---|---|
|
| |||||
| Cataract, n = 124 | 47 (38%) | 39 (83%) | 16 (34%) | 7 (15%) | 3 (6%) |
| Glaucoma, n = 305 | 117 (38%) | 82 (70%) | 50 (42%) | 20 (17%) | 0 (0%) |
| Narrow angle, n = 136 | 41 (30%) | 41 (100%) | 18 (44%) | 25 (61%) | 0 (0%) |
| Retinal disorders, n = 29 | 14 (48%) | 10 (71%) | 11 (79%) | 6 (43%) | 0 (0%) |
| Macular degeneration, n = 9 | 0 (0%) | 0 (0%) | 0 (0%) | NA | NA |
NA indicates not applicable; Rx = Prescription for glasses.
Percentage based on patients reached.